These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract. Malet A; Lluch M; Valero AL; Casanovas M Allergol Immunopathol (Madr); 1994; 22(5):226-32. PubMed ID: 7840025 [TBL] [Abstract][Full Text] [Related]
3. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. Holt PG; Sly PD; Sampson HA; Robinson P; Loh R; Lowenstein H; Calatroni A; Sayre P J Allergy Clin Immunol; 2013 Oct; 132(4):991-3.e1. PubMed ID: 23768574 [No Abstract] [Full Text] [Related]
4. Evaluation of immune parameters (including specific IgG4) during immunotherapy. Ruiz de León Loriga J; Lluch Pérez M; Valero Santiago A; Zamorano Calderón M; Huguet Casals J; Malet Casajuana A; García Calderón PA Allergol Immunopathol (Madr); 1989; 17(3):119-27. PubMed ID: 2479244 [TBL] [Abstract][Full Text] [Related]
5. Studies in hyposensitisation with Allpyral. Objective evaluation of the results. Fagerberg E; Nilzén A; Wiholm S Acta Allergol; 1972 Feb; 27(1):1-14. PubMed ID: 5067419 [No Abstract] [Full Text] [Related]
6. Broad perspectives of allergen specific immunotherapy. Thomas WR Hum Vaccin Immunother; 2017 Oct; 13(10):2385-2389. PubMed ID: 28933669 [No Abstract] [Full Text] [Related]
7. Specific immunotherapy by different allergen applications: subcutaneous, sublingual, oral or rectal administration and lymph node injection. Kleine-Tebbe J Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():87-95; discussion 95. PubMed ID: 20799448 [No Abstract] [Full Text] [Related]
8. [Specific immunotherapy in allergies--evaluation of current status]. Jarisch R; Hemmer W Wien Med Wochenschr; 1996; 146(15):422-5. PubMed ID: 9012204 [TBL] [Abstract][Full Text] [Related]
9. Decorating and loading ghosts with allergens for allergen immunotherapy. Fanuel S; Tabesh S; Rajani HF; Heidari S; Sadroddiny E; Kardar GA Hum Vaccin Immunother; 2017 Oct; 13(10):2428-2433. PubMed ID: 28934008 [TBL] [Abstract][Full Text] [Related]
10. [The treatment of atopic rhinitis in children with an accelerated variant of specific immunotherapy]. Gamzatova AA; Gadzhimirzaev GA Vestn Otorinolaringol; 1994; (5-6):33-7. PubMed ID: 7856017 [TBL] [Abstract][Full Text] [Related]
11. Toll-like receptors as targets for enhancing the efficacy of immunotherapy. Mutschlechner S; Deifl S; Bohle B Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():296-301; discussion 301-2. PubMed ID: 20799474 [No Abstract] [Full Text] [Related]
13. Does SIT to Der p protect from snail sensitization? Meglio P; Plantamura M; Arabito E; Falagiani P; Torre A; Rossi P Allergy; 2002 Sep; 57(9):868-9. PubMed ID: 12169197 [No Abstract] [Full Text] [Related]
14. [Specific immunotherapy using the slow alpha fraction of Dermatophagoides pteronyssinus. Efficacy; tolerance]. Sabbah A; Ascencio M; Mir F Allerg Immunol (Paris); 1989 Nov; 21(9):344-51. PubMed ID: 2624679 [TBL] [Abstract][Full Text] [Related]
15. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. Tabar AI; Echechipía S; García BE; Olaguibel JM; Lizaso MT; Gómez B; Aldunate MT; Martin S; Marcotegui F J Allergy Clin Immunol; 2005 Jul; 116(1):109-18. PubMed ID: 15990782 [TBL] [Abstract][Full Text] [Related]